Pfizer Inc. (PFE)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-04) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-03) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-04) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-05) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-04-29) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-04) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-29) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-30) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-01) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-01-30) · 99.1 | 8-K (2023-12-14) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-10-31) · 99.1 | 8-K (2023-10-13) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Statements of Income | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Comprehensive Income/(loss) (unaudited) | — |
|
| Consolidated Statements of Comprehensive Income | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Equity | ||
| Consolidated Statements of Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests | ||
| Acquisition and Equity-method Investment | — |
|
| Acquisition, In-licensing Arrangement and Sale of Investment | — |
|
| Acquisition, In-licensing Arrangement, Sale of Investment and Research and Development Arrangement | — |
|
| Acquisitions, Divestitures, Equity-method Investment and Research and Development Arrangement | — |
|
| Acquisitions, Divestitures, Equity-method Investments, Collaborative Arrangements and Research and Development Arrangement | — |
|
| Acquisitions, Divestitures, Equity-method Investments, Collaborative Arrangements, Research and Development Arrangements and In-licensing Arrangements | — |
|
| Acquisitions, Divestitures, Equity-method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement | — |
|
| Basis of Presentation and Significant Accounting Policies | ||
| Contingencies and Certain Commitments | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Earnings Per Common Share Attributable To Pfizer Inc. Common Shareholders | ||
| Earnings/(loss) Per Common Share Attributable To Pfizer Inc. Common Shareholders | — |
|
| Equity | — |
|
| Financial Instruments | ||
| Identifiable Intangible Assets | — |
|
| Identifiable Intangible Assets and Goodwill | ||
| Identifiable Intangible Assets, Net and Goodwill | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | — |
|
| Other (income)/deductionsnet | ||
| Other (income)/deductionsânet | — |
|
| Other Financial Information | ||
| Pay Vs Performance Disclosure | ||
| Pension and Postretirement Benefit Plans | — |
|
| Pension and Postretirement Benefit Plans and Defined Contribution Plans | — |
|
| Property, Plant and Equipment | — |
|
| Property, Plant and Equipment, Net | — |
|
| Research and Development and In-licensing Arrangement | — |
|
| Research and Development Arrangement | — |
|
| Restructuring Charges and Other Costs Associated With Acquisitions and Cost-reduction/productivity Initiatives | ||
| Segment, Geographic and Other Revenue Information | ||
| Share-based Payments | — |
|
| Subsequent Event | — |
|
| Tax Matters | ||